The Antidepressant Effect of Right Prefrontal Low Frequency rTMS in an Accelerated Treatment Model

NCT ID: NCT03868774

Last Updated: 2019-08-19

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: NA
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-09-30
• Study Completion Date: 2019-09-30

Brief Summary

Repetitive transcranial magnetic stimulation has appeared a new non-invasive antidepressant method, which implies non-convulsive focal stimulation of the prefrontal cortex of the brain through a time varying magnetic field. The method is associated with minimal side effects limited to local discomfort and especially no impact on cognitive function. The method has been approved for the treatment of depression in Canada, USA and a couple of European countries. The department for Affective Disorders, Aarhus University Hospital has used rTMS as add-on to conventional antidepressant treatment in the outpatient clinic since 2015. A single treatment course covers 20 sessions given on 20 consecutive days. The demand for daily treatment and attendance for 20 days is resource demanding for both the patient and the clinic. In consequence the investigators want to examine the antidepressant effect of an accelerated stimulus model comparing the outcome of the standard model ( 20 days) with a treatment model covering the same number of stimuli given within one week.

Detailed Description

rTMS has appeared a potential new non-invasive antidepressant method, which implies nonconvulsive focal stimulation of the brain through a time varying magnetic field. RTMS is based on the principle of electromagnetism. An electromagnetic coil placed on the scalp produces a time-varying magnetic field that penetrates the scalp and skull unattenuated and gives rise to a current in the proximity of the cerebral cortex as well as functionally connected parts of the brain. Research on rTMS reports of minimal side effects of the method.

Previous research indicates that the antidepressant effect of rTMS is associated with specific stimulation of the dorsolateral prefrontal cortex. The stimulus frequency has shown to play a key role in the mechanisms of action of rTMS. Previous animal studies have shown that low frequency rTMS is associated with long term inhibition of neuronal activity (long term depression), while high frequency stimulation is followed by prolonged activation (long term potentiation). The majority of clinically controlled studies have used high frequency stimulation of the left frontal cortex, which has been approved by the USA and later in the European Union for the treatment of depression. Fewer studies have used right prefrontal low frequency rTMS, which has less side effects, such as local discomfort and a lower risk of releasing epileptic seizures, than high frequency stimulation. Randomized controlled trials and meta-analysis have shown that both stimulus models have a clinically, significant antidepressant effect at the same level as antidepressant drugs, and recent research clearly indicates that low frequency rTMS of the right prefrontal cortex is associated with an antidepressant effect at the same level as the high frequency model. The issue indicates that low frequency due to the more advantageous side effect profile should be the stimulus model of choice in a clinical setting.

The Department for Affective Disorders, Aarhus University Hospital has taken part in rTMS research since 1999, and the outpatient clinic has used low frequency rTMS as add-on to conventional antidepressant treatment since 2015. A single treatment course covers 20 treatment sessions given on 20 consecutive days. The demand for daily treatment and attendance in the outpatient clinic for 20 days is resource demanding both for the patient and the clinic. In consequence the investigators want to examine the antidepressant effect of an accelerated stimulus model comparing the antidepressant efficacy of conventional treatment (20 days) with a treatment model covering the same number of stimuli given within one week.The study is lightening the significance of the association between the number of stimulus pulses, the length of the total treatment period and the antidepressant effect. Patients suffering for depression may benefit from the outcome of the study by obtaining an accelerated antidepressant effect from a less time consuming stimulus model. The outcome of the study may be implemented in clinical practice from day one.

Conditions

Depression

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

rTMS standard

Low frequency (1 Hz), rTMS 20 sessions given on 20 consecutive days ( except weekends)

Group Type: ACTIVE_COMPARATOR

repetitive transcranial magnetic stimulation

Intervention Type: PROCEDURE

rTMS is a new non-invasive antidepressant method, which implies non-convulsive focal stimulation of the prefrontal cortex of the brain through a time varying magnetic field.

rTMS accelerated model

Low frequency ( 1 Hz), right prefrontal transcranial magnetic stimulation. 20 sessions given on 5 consecutive days ( 4 sessions each day)

Group Type: ACTIVE_COMPARATOR

repetitive transcranial magnetic stimulation

Intervention Type: PROCEDURE

rTMS is a new non-invasive antidepressant method, which implies non-convulsive focal stimulation of the prefrontal cortex of the brain through a time varying magnetic field.

Interventions

repetitive transcranial magnetic stimulation

rTMS is a new non-invasive antidepressant method, which implies non-convulsive focal stimulation of the prefrontal cortex of the brain through a time varying magnetic field.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

1. Moderate-severe uni- and bipolar depression according to the International Classification of Diseases (ICD-10)

2. A Hamilton scale score (HDS-17) of ≥ 18 and/or a sub-scale (HDSS) score of ≥ 9 within 24-48 hours before the first treatment

Exclusion Criteria

1. Organic brain disease.

2. Epileptic seizure < 2 years

3. Patients with implanted metal parts in the brain or chest

4. Patients with pacemaker

5. Medical diseases with cerebral impact

6. Serious suicidal danger

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Aarhus

OTHER

Sponsor Role: lead

Responsible Party

Poul Erik Buchholtz

senior researcher

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Poul Erik Buchholtz, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Depression and Anxiety

Other Identifiers

ADA

Identifier Type: -

Identifier Source: org_study_id